Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor

Ripretinib is a switch control KIT kinase inhibitor approved for treatment of adults with advanced gastrointestinal stromal tumors who received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib and its active metabolite (DP‐5439) are cleared mainly via cytochrome P450...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyan, Shelton, Mark J, Wang, Jing, Meade, Julie, Ruiz‐Soto, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790248/
https://www.ncbi.nlm.nih.gov/pubmed/35560823
http://dx.doi.org/10.1002/cpdd.1110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790248/
https://www.ncbi.nlm.nih.gov/pubmed/35560823
http://dx.doi.org/10.1002/cpdd.1110

Ejemplares similares